panCELLa-A Pluristyx Company
Accelerating the Development of Advanced Cell Therapies

PanCELLa is a pioneering company in the development of pluripotent stem cells and gene editing technology for creating “off-the-shelf” cell therapies. Its proprietary platform includes gene editing tools and techniques for modifying pluripotent stem cells, making it possible to engineer cells to combat diseases such as cancer, genetic disorders, and autoimmune diseases.
Pluristyx has established itself as a leading provider of cell therapy solutions, focusing on delivering high-quality, consistent, and scalable starting material and manufacturing processes for cell therapies. The company’s proprietary platform leverages an innovative RNA-based approach that enables the rapid and efficient generation of induced pluripotent stem cells (iPSCs) compared to traditional methods. Its advanced manufacturing development facilities, equipped with automated cell culture systems, enable the production of significant quantities of premium cells for research and development and transition for clinical use.

The two companies recognized the potential for synergies resulting from their complementary competencies, leading to a merger agreement and the establishment of a unified organization. The newly formed company is equipped to provide clients with high-quality iPSC lines that allow allogeneic cell therapy from research to clinical and commercial scale. The merger’s primary goal is to offer capabilities and enable clients an accelerated path into the market.

Cell therapies are increasingly recognized over traditional pharmaceuticals for offering enduring cures instead of symptomatic relief. Additionally, they can be personalized to the individual, using their cells, thereby mitigating the possibility of rejection and enhancing their efficacy. The merger will provide a much-needed boost to advancing and commercializing cutting-edge cell therapies, meeting the ever-increasing demand for such therapies.

The merger will amalgamate Pluristyx’s proficiency in cell therapy development with panCELLa’s avant-garde technology for generating high-quality, scalable, and consistent pluripotent stem cells. The combined enterprise will deliver comprehensive, state-of-the-art solutions to its clientele by fusing panCELLa’s remarkable genetic editing technologies and patents with Pluristyx’s capacity to produce induced pluripotent stem cell (iPSC) lines at a commercial scale. This integration of technology and service offerings will expedite the delivery of groundbreaking cell therapies to patients as they are needed.

“The new entity offers end-to-end stem cell services to clients, from cell sourcing and manufacturing to clinical development and commercialization,” says Brian Hawkins, CTO of Pluristyx.

After the merger, a comprehensive platform will be forged, allowing for the advancement of a vast range of cell therapies, encompassing gene-edited cells, CAR-T cells, and iPSCs. This multifaceted platform will facilitate the parallel development of numerous products and employ a scalable, efficient manufacturing process that permits the cost-effective production of cell therapies.

Remarkably, the superior quality iPSCs generated by the merged organization through an exclusive mRNA-based technology can be procured under a ‘try-before-you-buy’ research evaluation model. This research evaluation model allows groups to evaluate both the underlying iPSC line and genetically edited variants for a low upfront fee prior to making a licensing decision. Common genetic edits available under our research evaluation model include our proprietary iACT® and FailSafe® technologies, which respectively allow cells to avoid rejection by the patient’s immune system and provide a means to eliminate cells from patients when they are no longer needed.

By providing end-to-end services to clients throughout their product development journey, the new entity will be well-equipped to accelerate the delivery of revolutionary treatments to patients and provide the fastest path to gene-edited iPSC-based therapies. The collaboration is poised to revolutionize the production and delivery of cell therapies, offering a promising outlook for addressing previously untreatable diseases.